Dunn Edmund
SEC insider (Form 3/4/5 filer). CIK 0001989401. Principal Accounting Officer at Monte Rosa Therapeutics, Inc. (GLUE). 8 reported Form 4/5 transactions since Sep 2024; latest on Mar 4, 2026. Located in BOSTON, MA.
Companies Dunn Edmund has filed insider reports for
- Monte Rosa Therapeutics, Inc. (GLUE): Officer, Principal Accounting Officer
Dunn Edmund
CIK: 0001989401
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
Monte Rosa Therapeutics, Inc.
Discretionary Trading P&L
Holdings
Transaction History (8 total)
- Mar 4, 2026GLUE
Monte Rosa Therapeutics, Inc.
SaleDirect139 shares at avg. $17.96$2K - Mar 2, 2026GLUE
Monte Rosa Therapeutics, Inc.
SaleDirect536 shares at avg. $17.50$9K - Mar 2, 2026GLUE
Monte Rosa Therapeutics, Inc.
ExerciseDirect536 shares at avg. $13.41$7K - Feb 27, 2026GLUE
Monte Rosa Therapeutics, Inc.
ExerciseDirect25.2K shares at avg. $13.41$337K - Feb 27, 2026GLUE
Monte Rosa Therapeutics, Inc.
SaleDirect25.2K shares at avg. $18.10$456K - Jan 5, 2026GLUE
Monte Rosa Therapeutics, Inc.
SaleDirect1K shares at avg. $15.17$16K - Jun 3, 2025GLUE
Monte Rosa Therapeutics, Inc.
SaleDirect2.1K shares at avg. $4.45$9K - Jan 2, 2025GLUE
Monte Rosa Therapeutics, Inc.
AwardDirect11.9K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Mar 4, 2026 | GLUE Monte Rosa Therapeutics, Inc. | Sale | 139 | $17.96 | $2,496 | Direct |
| Mar 2, 2026 | GLUE Monte Rosa Therapeutics, Inc. | Sale | 536 | $17.50 | $9,380 | Direct |
| Mar 2, 2026 | GLUE Monte Rosa Therapeutics, Inc. | Exercise | 536 | $13.41 | $7,188 | Direct |
| Feb 27, 2026 | GLUE Monte Rosa Therapeutics, Inc. | Exercise | 25,164 | $13.41 | $337,449 | Direct |
| Feb 27, 2026 | GLUE Monte Rosa Therapeutics, Inc. | Sale | 25,164 | $18.10 | $455,506 | Direct |
| Jan 5, 2026 | GLUE Monte Rosa Therapeutics, Inc. | Sale | 1,039 | $15.17 | $15,762 | Direct |
| Jun 3, 2025 | GLUE Monte Rosa Therapeutics, Inc. | Sale | 2,062 | $4.45 | $9,174 | Direct |
| Jan 2, 2025 | GLUE Monte Rosa Therapeutics, Inc. | Award | 11,850 | - | $0 | Direct |
1-8 of 8 transactions